Results 1 to 10 of about 66,981 (270)

Obstructive Hypertrophic Cardiomyopathy and Takotsubo Syndrome: How to Deal With Left Ventricular Ballooning? [PDF]

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2023
Currently, there are 2 proposed causes of acute left ventricular ballooning. The first is the most cited hypothesis that ballooning is caused by direct catecholamine toxicity on cardiomyocytes or by microvascular ischemia.
R. Citro, M. Bellino, E. Merli, D. Di Vece, M. Sherrid   +4 more
semanticscholar   +2 more sources

HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY

Alʹmanah Kliničeskoj Mediciny, 2016
Hypertrophic cardiomyopathy (HCMP) is a relatively common disease with genetic predisposition, that is widely spread irrespective of gender, race or ethnicity. The cause of this pathology are mutations of genes encoding synthesis of contracting proteins.
A. G. Osiev, R. A. Naydenov, E. I. Kretov, N. R. Obedinskaya, V. P. Kurbatov   +4 more
doaj   +3 more sources

Effects of septal myectomy on left atrial and left ventricular function in obstructive hypertrophic cardiomyopathy [PDF]

ESC Heart Failure, 2023
Mechanical function of the left atrium (LA) and the left ventricle (LV) has been demonstrated to be a prognostic factor in patients with hypertrophic cardiomyopathy (HCM).
Kyungeun Ha, K. Choi, Hee-Jung Lee, S. Gwak, Kyu Kim, Iksung Cho, G. Hong, J. Ha, C. Shim   +8 more
semanticscholar   +2 more sources

Effect of beta‐blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy [PDF]

European Journal of Heart Failure, 2022
In the EXPLORER‐HCM trial, mavacamten improved exercise capacity and symptoms in patients with obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten effects on the primary endpoint, a composite of peak oxygen consumption (VO2) and New York Heart ...
M. Wheeler, D. Jacoby, P. Elliott, S. Saberi, Sheila M. Hegde, N. Lakdawala, J. Myers, A. Sehnert, J. Edelberg, Wanying Li, I. Olivotto   +10 more
semanticscholar   +2 more sources

Effects of Alcohol Septal Ablation on Exercise Hemodynamics, Symptoms, and Quality of Life in Obstructive Hypertrophic Cardiomyopathy [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The impact of alcohol septal ablation (ASA) on exercise hemodynamics, symptoms, and quality of life in patients with obstructive hypertrophic cardiomyopathy is poorly described according to contemporary standards.
Anne M. Dybro, Torsten B. Rasmussen, Roni R. Nielsen, Bertil T. Ladefoged, Anders L. D. Pedersen, Christian J. Terkelsen, Mads J. Andersen, Morten K. Jensen, Steen H. Poulsen   +8 more
doaj   +2 more sources

Cardiovascular Hospitalizations Burden Following Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Longer‐term morbidity post septal myectomy (SM) in obstructive hypertrophic cardiomyopathy has not been well characterized at a national level.
Ahmed Altibi, Miriam Elman, Hailey Volk, Mohammad Alqabani, Michael Butzner, Howard Song, Ahmad Masri   +6 more
doaj   +2 more sources

Eighteen‐Month Real‐World Experience Using Mavacamten for Treatment of Obstructive Hypertrophic Cardiomyopathy in a Racially Diverse Population

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Patients with obstructive hypertrophic cardiomyopathy have increased symptomatic burden. Mavacamten was recently approved for treatment of obstructive hypertrophic cardiomyopathy based on 2 randomized controlled trials.
Diego Ramonfaur, Alessio Gasperetti, Victoria E. Blake, Bryana Rivers, Ali A. Kassamali, Edward K. Kasper, Lili A. Barouch, Katherine C. Wu, Jose A. Madrazo, Richard T. Carrick   +9 more
doaj   +2 more sources

Outcome of Alcohol Septal Ablation in Mildly Symptomatic Patients With Hypertrophic Obstructive Cardiomyopathy: A Long‐Term Follow‐Up Study Based on the Euro‐Alcohol Septal Ablation Registry [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
Background The long‐term efficacy and safety of alcohol septal ablation (ASA) in patients with highly symptomatic hypertrophic obstructive cardiomyopathy has been demonstrated.
Josef Veselka, Lothar Faber, Max Liebregts, Robert Cooper, Jaroslav Januska, Jan Krejci, Thomas Bartel, Maciej Dabrowski, Peter Riis Hansen, Vibeke Marie Almaas, Hubert Seggewiss, Dieter Horstkotte, Radka Adlova, Henning Bundgaard, Jurriën ten Berg, Rodney Hilton Stables, Morten Kvistholm Jensen   +16 more
doaj   +3 more sources

Long-Term Real-World Outcomes of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy up to 108 Weeks. [PDF]

J Clin Med
Reza N, Dubey A, Mahmud N, Austin MA, Duqueney E, Patel P, Boakye E, Marzolf A, Hornsby N, de Feria A, Carattini T, Schuler P, Owens AT.   +12 more
europepmc   +3 more sources

Hypertrophic Obstructive Cardiomyopathy [PDF]

Deutsches Ärzteblatt international, 2019
Hypertrophic cardiomyopathy (HCM) is caused by mutations in a number of genes. Its prevalence is 0.2% to 0.6%.This review is based on publications retrieved by a selective literature search and on the authors' clinical experi- ence.70% of patients with HCM suffer from the obstructive type of the condition, clinically characterized by highly dynamic and
Angelika, Batzner, Hans-Joachim, Schäfers, Konstantin V, Borisov, Hubert, Seggewiß   +3 more
openaire   +3 more sources